192: Treatment of unexplained syncope: A multicenter, randomized trial of cardiac pacing guided by adenosine 5’-triphosphate testing  by Flammang, Daniel et al.
© Elsevier Masson SAS. All rights reserved.
 
62 Archives of Cardiovascular Diseases Supplements (2013) 5, 57-69
189
Clinical and electrophysiological data of patients with first degree AV
block and AV node reentrant tachycardia
Béatrice Brembilla-Perrot (1), Vladimir Manenti (1), Maxime Benichou (2),
Jean Marc Sellal (2), Pierre Yves Zinzius (2), Mahesh Pauriah (2), Gabriel
Cismaru (2), Christian De Chillou (1), Daniel Beurrier (1), Hugues
Blangy (1)
(1) CHU of Brabois, cardiologie, Vandoeuvre Les ancy, France – (2) Car-
diologie, CHU de Brabois, Vandoeuvre Les ancy, France
Typical atrioventricular (AV) node re-entrant tachycardia (AVNRT) occurs
in patients with dual AV nodal pathway, a rapid pathway used for retrograde
conduction and a slow pathway used for the anterograde conduction. In sinus
rhythm, the patients have generally the signs of conduction through the rapid
pathway with a normal or short PR interval. The purpose of the study was to
evaluate the prevalence of patients with 1st degree AV block and with AVNRT
and their clinical characteristics.
Methods: 973 patients, 348 males, 625 females, were admitted for typical
AVNRT. They were aged from 6 to 90 years (mean age 50±19). Initial ECG
and clinical data were collected. Electrophysiological study was systematic.
Results: Spontaneous 1st degree AV block (AVB) was rare and noted in
7 patients. The prevalence of the association 1st degree AV block and AVNRT
was 0.7%. Five patients complained of AVNRT at exercise. Two patients had
an ischemic heart disease. Patients with AVB were significantly older (71.5±
16 years) than patients without AVB (50±19)(p<0.002). AVNRT was induced
in control state in 4 patients. The rate of tachycardia was slow between 130 and
150 bpm. AVNRT was induced after isoproterenol in 3 patients and the rate
was higher (180 to 200 bpm). Ablation of slow pathway was performed in
6 patients. Transitory 2nd degree AVB was noted in 1 patient. AVNRT was not
inducible after ablation. PR interval remained unchanged. At atrial pacing, the
rate of 2nd degree AVB occurrence decreased, due to the disappearance of the
conduction through the slow pathway. Two patients developed transitory well-
tolerated 2nd degree AVB one day after ablation. One patient presented
apparent sinus bradycardia related to a concealed conduction through AV node.
One year after ablation none of the patients required pacemaker implantation
and patients were free of tachycardia.
Conclusions: The occurrence of AVNRT in patients with 1st degree AV
block is exceptional and concerns old patients. Ablation of slow pathway
might be safely performed without a need of pacemaker implantation. Transi-
tory 2nd degree AVB can be noted the day after ablation.
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Electrophysiological study is the main method for the detection of patients
with a Wolff-Parkinson-White syndrome (WPW) at risk of adverse presenta-
tion (resuscitated ventricular fibrillation (VF), documented life-threatening
arrhythmia): the protocol is debated. The purpose of the study was to look in
how many patients with WPW-related adverse presentation, atrial fibrillation
(AF) or atrial tachycardia with the shortest RR cycle length (CL) with 1/1
conduction over accessory pathway (AP)<250 msec was induced in control
state (CS) and when isoproterenol was required.
Methods: 63 patients, mean age 38±18, were referred for WPW-related
adverse presentation (VF 6, other 56). EPS included in CS atrial pacing and
measurement of the shortest CL with 1/1 conduction over AP and pro-
grammed stimulation with 1 and 2 extrastimuli. AP effective refractory period
(ERP) was determined. In absence of induction of a tachycardia with a CL
<250 msec, isoproterenol (0.02 to 1 µg. min-1) was infused to increase sinus
rate to 130 bpm; the protocol was repeated.
Results: Mean shortest CL conducted over AP was 223±30 msec in CS,
192±25 msec after isoproterenol. APERP was 225±29 msec in CS, 191±19
msec after isoproterenol. Atrioventricular orthodromic tachycardia (AVRT)
was induced in 34 patients (54%), antidromic tachycardia (ATD) in 13 (21%),
AF in 43 (68%). Criteria for a malignant form (induction of AF or ATD with
a shortest CL <250 mesc) were noted in 42 patients (67%) in CS and were
obtained after isoproterenol in remaining 21 patients (33%). Among these
patients, 12 had inducible tachycardia in CS (AVRT (n=6), ATD (n=3), AF
(n=3) but the shortest CL was >240 msec. A tachycardia was only induced
after isoproterenol in 9 patients (14%).
Conclusions: Infusion of isoproterenol should be systematic when WPW
is evaluated. EPS performed only in CS missed at least 14% of patients at risk
of life-threatening arrhythmias who had no inducible supraventricular tachyar-
rhythmia and 33% of patients with a WPW without the classical criteria for a
malignant form. Isoproterenol increased the sensitivity of EPS for the detec-
tion of malignant form from 67 to 100%.
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Introduction: The Epicor system ® is based on high intensity focused
ultrasound (HIFU) energy used for creating a wide circumferential linear left
atrial lesion encircling both left atrial posterior wall and pulmonary veins (box
lesion) and provides long-term cure in patients with atrial fibrillation under-
going heart surgery. Whether if acute complete disconnection of the box
lesion is achieved by application of HIFU is unknown.
Methods: bipolar pacing and detection into the box lesion was studied in
9 pts (5 men, 77 ±18 yo) undergoing heart surgery (5 aortic valve replacement,
3 mitral valve repair or replacement and one coronary by-pass) using bipolar
electrophysiological catheter and a real time telemetry (Medtronic CareLink®
programmer), just after completion of the ablation process on the beating heart
prior to initiation of extracorporeal circulation. Sinus rhythm was present or
obtained using internal cardioversion in each before the ablation process.
Results: Entrance block was absent in 7 (1 to 1 conduction from sinus
rhythm inside the box lesion), undetermined in one and present in one (disso-
ciated slow local rhythm). Exit block was lacking in 6 (capture of the cardiac
rate by pacing inside the box lesion) and present in 3 (dissociated sinus
rhythm from the paced area).
Conclusion: Acute complete block of the Epicor ® HIFU induced box
lesion is lacking in the vast majority of pts despite completion of the energy
deliverance according to the automated ablation process. Whether block later
happens, or whether supplementary applications would increase the electro-
physiological and clinical success rate is unknown.
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Background: The origin of 40% of syncope remains unknown even after
a complete diagnostic work-up. Previous studies have suggested that ade-
nosine 5’-triphosphate (ATP) testing has value in selecting successful therapy.
This patient-blinded, multicenter, randomized superiority trial tested whether,
in patients with syncope of unknown origin (SUO), selecting cardiac pacing
in those with a positive ATP test results in fewer recurrences than those who
do not receive pacing.
Methods and Results: From 2000 to 2005, 80 consenting patients (mean
age 75.9±7.7 years; 81% women; 56% without diagnosed structural heart
disease) with syncope of unknown origin and atrioventricular or sinoatrial
block lasting longer than 10 seconds (average 17.9±6.8 seconds) under ATP
administration (20 mg IV bolus) were recruited from 10 hospitals, implanted
with programmable pacemakers and randomized to either active pacing (dual-
chamber pacing at 70 beats per minute (bpm) or backup pacing (atrial pacing
at 30 bpm). Patients were followed regularly for up to five years for any syn-
cope recurrence, the primary outcome.
Mean follow-up was 16 months. Syncope recurred in eight (21%) of
39 patients randomized to active pacing and in 27 (66%) of 41 randomized to
backup pacing (control), yielding a hazard ratio of 0.25 (95% CI: 0.12-0.56).
After recurrence, the 27 recurrent control patients were reprogrammed to
active pacing and only one reported subsequent syncope.
Conclusions: This study suggests that, in elderly patients with syncope of
unknown origin and positive ATP tests, active dual-chamber pacing reduces
syncope recurrence risk by 75% (95% confidence interval, 44-88).
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Background: Extracellular adenosine-5’-triphosphate (ATP) suppresses
cardiac pacemakers' automaticity and AV nodal conduction directly and indi-
rectly by adenosine and a triggered cardio-cardiac vagal reflex. This action
constitutes the rationale for the ATP-test, a diagnostic tools aimed to identify
patients with syncope of unknown origin (SUO) who could benefit from pace-
maker therapy. Two criteria have been used to determine a positive outcome
of the ATP test: (i) the duration of ATP-induced cardiac pause (CP) due to
AV nodal conduction block or suppressed sinus node, ignoring escape beats,
and (ii) the maximal RR interval irrespective of the origin of the QRS com-
plexes (RRmax). The test is deemed positive when CP is >10 sec or RRmax
>6 sec Two contrasting conclusions regarding the utility of the test have been
reached using these two criteria. The aim of the current post-hoc study, was
to explain the discrepancy between the two conclusions.
Methods: ATP test consists on an I.V. bolus injection of 20 mg of ATP
into an antecubital vein. We analyzed data of 33 patients-cohort derived from
a multicenter study having incorporated 80 SUO patients (Circulation
2012;125:31-6), in which the ATP-test was positive using the CP duration and
negative using the RRmax interval. The 47 remaining patients had both tests
positive and were excluded from this analysis.
Results: A dual chamber pacemaker was implanted in all 33 patients: in
14 and 19 patients the pacemaker was programmed for DDD70 bpm and
AAI30 bpm (control) pacing modes, respectively. Syncope recurred in only
one of the 14 DDD70 patients (7%) during a follow up period of 17.0±8.6
months, but in 10 of the 19 AAI30 patients (53%) during 5.3±5.2 months
(p<0.009).
Conclusion: This study shows that ATP-test is a useful diagnostic tool for
identifying patients with bradycardic syncope who might benefit from pacing
therapy when the CP criterion -and not the RRmax criterion- is used to deter-
mine the outcome of the test.
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Non valvular atrial fibrillation (NVAF) is associated with an increased risk
of stroke. CHADS2 score is used to guide thromboporphylaxis among patients
with NVAF. Copeptine a vasoactive peptide reflecting cardiac stress has been
recently evaluated in combination with Troponin to exclude the diagnosis of
acute coronary syndrome but had never been tested in atrial fibrillation. We
evaluated the relation between the CHADS2 score and several biomarkers
representing multiple pathways implicated in non valvular atrial fibrillation.
Methods: Plasma concentrations of Troponin I (TnI), BNP, mid-regional
proatrial natriuretic peptide (MR-proANP)), hs- CRP, D-dimer and mid-
copeptin (CT-proAVP)) were measured at the time of admission in 45 NVAF
consecutive patients. The association between the median values of these
markers, clinical characteristics, transthoracic echocardiographic parameters
and stroke risk stratification as assessed by the CHADS2 score was tested.
Results: Baseline patients characteristics were as follows: mean age was
64.6±14.9 years, 56% were men, 51% had hypertension, and 7% had diabetes. In
seven patients (16%) NVAF was associated with acute heart failure. Thirtheen
patients (29%) had a prior AF. NVAF was paroxysmal in 67% of patients Mean
LV EF was 54.3±15.7%.and mean LA surface was 21.6±7.1 cm².
Mean CHADS score was 1.1±1 
Table 1 depicted the level of each biomarkers according to the CHADS2
score ANP, Copeptine, hs-CRP, D-dimer levels were increased with the
increased of the CHADS2 score.
Conclusion: Copeptine levels were found to be higher in patients at higher
risk of thrombo embolism as assessed by CHADS2 score.
Table 1 – Results
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The management and prognosis of heart diseases (HD) or arrhythmias may
depend on the patient gender. The purpose of the study was to look for the
influence of gender on the indications and the long-term results of ablation of
atrial flutter (AFl).
Methods: 965 patients, 743 males, 222 females (23%), mean age 64±
12 years were consecutively referred for radiofrequency ablation of recurrent
CHADS2=0 CHADS2=1 CHADS2 >= 2
N=15
median (IQR)
n=14
median (IQR)
n=16
median (IQR) 
 
p
BNP (pg/ml) 244 
(96-378)
394.5 
(120-524)
433.5 
(248.5-644)
0,1422
ANP (pmol/l) 108.9 
(86.56-188.9)
257.2
(122.6-391.4)
305.05
(244.75-406.3)
0,0037
Troponin I (ng/ml) 0.04 
(0.04-0.04)
0.04 
(0.04-0.04)
0.04 
(0.04-0.06)
0,4919
Copeptine (pmol/l) 7.39 
(5-9.48)
8.005 
(5-17.21)
13.685 
(9.145-26.845)
0,0221
Hs CRP (mg/l) 3 (1.53-10) 4.085 (1.96-10) 10 (6.53-34.05) 0,0247
D – dimer (ng/ml) 267 (215-366) 682 (250-751) 816 (516-1055) 0,0346
